

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**EXTENSION OF LONG STOP DATE OF (1) THE SUBSCRIPTION
AGREEMENT IN RELATION TO THE SUBSCRIPTION;
AND
(2) THE ALTERATION CONSENT LETTERS IN RELATION
TO THE ALTERATION OF TERMS**

References are made to the announcements of Wai Chun Bio-Technology Limited (the “**Company**”) dated 22 December 2022 in respect of connected transactions in relation to (i) proposed issue of New Convertible Bonds under specific mandate; and (ii) proposed alteration to the terms of Existing Convertible Bonds, dated 10 January 2023 in relation to (i) proposed Share Consolidation; and (ii) proposed change of conversion price of convertible bonds, dated 9 February 2023 in relation to the delay in despatch of Circular, and dated 10 February 2023 in relation to the revised expected timetable for the Share Consolidation (together, the “**Announcements**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

THE SECOND SUPPLEMENTARY AGREEMENT

Pursuant to the terms and conditions of the Subscription Agreement (as amended by the supplementary agreement dated 10 January 2023 entered into between the Company and Chinese Success), completion of the Subscription Agreement is subject to the conditions precedent being fulfilled or waived (as the case may be) on or before 28 February 2023 (or such other date as may be agreed by the Company and Chinese Success) (the “**Long Stop Date of the Subscription Agreement**”).

On 13 February 2023 (after trading hours), the Company and Chinese Success entered into a second supplementary agreement, pursuant to which the parties agreed to extend the Long Stop Date of the Subscription Agreement to 31 March 2023 (or such other date as may be agreed by the Company and Chinese Success) as additional time is required for the Company and Chinese Success to procure the fulfillment of the conditions precedent.

Save for the above, all other terms and conditions of the Subscription Agreement (as amended by the supplementary agreement dated 10 January 2023 entered into between the Company and Chinese Success) shall remain in full force and effect.

THE SECOND SUPPLEMENTARY LETTERS

Pursuant to the terms and conditions of the Alteration Consent Letters (as amended by the supplementary letters dated 10 January 2023 entered into between the Company and the Existing Bondholders), completion of the alteration of the terms of the Existing Convertible Bonds is subject to the conditions precedent being fulfilled on or before 28 February 2023 (or such other date as may be agreed by the Company and the Existing Bondholders) (the “**Long Stop Date of the Alteration Consent Letters**”).

On 13 February 2023 (after trading hours), the Company and the Existing Bondholders entered into second supplementary letters, pursuant to which the parties agreed to extend the Long Stop Date of the Alteration Consent Letters to 31 March 2023 (or such other date as may be agreed by the Company and the Existing Bondholders) as additional time is required for the Company and the Existing Bondholders to procure the fulfillment of the conditions precedent.

Save for the above, all other terms and conditions of the Alteration Consent Letters (as amended by the supplementary letters dated 10 January 2023 entered into between the Company and the Existing Bondholders) shall remain in full force and effect.

Completion of the Subscription and the Alteration of Terms, which are subject to the fulfilment of the respective conditions precedent set out in the Subscription Agreement and the Alteration Consent Letters, may or may not take place. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares and other securities of the Company.

By Order of the Board
Wai Chun Bio-Technology Limited
Chan Cheuk Ho
Executive Director

Hong Kong, 13 February 2023

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Chan Cheuk Ho and three independent non-executive Directors, namely Ms. Hong Ting, Mr. Wan Bo and Mr. Hung Hoi Ming Raymond.